Luca Coccoli

459 total citations
16 papers, 289 citations indexed

About

Luca Coccoli is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Luca Coccoli has authored 16 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 6 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Luca Coccoli's work include Sarcoma Diagnosis and Treatment (11 papers), Neuroblastoma Research and Treatments (3 papers) and Vascular Tumors and Angiosarcomas (2 papers). Luca Coccoli is often cited by papers focused on Sarcoma Diagnosis and Treatment (11 papers), Neuroblastoma Research and Treatments (3 papers) and Vascular Tumors and Angiosarcomas (2 papers). Luca Coccoli collaborates with scholars based in Italy and United States. Luca Coccoli's co-authors include Paolo Ghirri, Antonio Boldrini, Armando Cuttano, Marco Bernardini, Marco Vuerich, Lucia Montanelli, I J Chopra, Ilaria Merusi, C. Mammoli and Aldo Pinchera and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Luca Coccoli

14 papers receiving 279 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luca Coccoli Italy 6 106 97 91 56 54 16 289
Merja B. Marttunen Finland 8 17 0.2× 36 0.4× 77 0.8× 50 0.9× 124 2.3× 9 389
Tereza Hálková Czechia 10 42 0.4× 41 0.4× 76 0.8× 91 1.6× 96 1.8× 22 355
Marinka S. Post Netherlands 8 37 0.3× 60 0.6× 223 2.5× 19 0.3× 19 0.4× 8 395
Florin Tripon Romania 12 25 0.2× 50 0.5× 13 0.1× 140 2.5× 38 0.7× 42 381
Svetlana Zorić Serbia 11 70 0.7× 16 0.2× 229 2.5× 62 1.1× 18 0.3× 24 432
Michael B. Ranke Germany 7 45 0.4× 89 0.9× 345 3.8× 149 2.7× 13 0.2× 11 474
Spyridon Gerou Greece 10 16 0.2× 36 0.4× 57 0.6× 147 2.6× 121 2.2× 31 393
S. C. Cwyfan Hughes United Kingdom 8 24 0.2× 28 0.3× 316 3.5× 102 1.8× 41 0.8× 8 364
Jürg Schwander Switzerland 9 31 0.3× 154 1.6× 296 3.3× 118 2.1× 45 0.8× 10 410
Linda A. Villani Canada 9 33 0.3× 60 0.6× 101 1.1× 218 3.9× 70 1.3× 16 388

Countries citing papers authored by Luca Coccoli

Since Specialization
Citations

This map shows the geographic impact of Luca Coccoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Coccoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Coccoli more than expected).

Fields of papers citing papers by Luca Coccoli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Coccoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Coccoli. The network helps show where Luca Coccoli may publish in the future.

Co-authorship network of co-authors of Luca Coccoli

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Coccoli. A scholar is included among the top collaborators of Luca Coccoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Coccoli. Luca Coccoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Andreani, Lorenzo, et al.. (2024). Can FDG-PET assess the response to chemotherapy and predict tissue necrosis in osteosarcoma and Ewing sarcoma?. SHILAP Revista de lepidopterología. 66(2). 196–202.
2.
Palmerini, Emanuela, Maria Rosaria Sapienza, Stefano Pileri, et al.. (2024). Phase II study in pediatric and AYA patients with non-metastatic high-grade extremity osteosarcoma with a risk-adapted strategy based on P-glycoprotein (ISG/OS-2): A correlative study on tumour immune microenvironment.. Journal of Clinical Oncology. 42(16_suppl). 11530–11530. 1 indexed citations
3.
Tirtei, Elisa, Veronica Sciannameo, Sebastian Dorin Asaftei, et al.. (2024). Prolonged 14-day continuous infusion of high-dose ifosfamide for patients with relapsed and refractory high-grade osteosarcoma: a retrospective multicentre cohort study. BMC Cancer. 24(1). 747–747. 2 indexed citations
4.
Tirtei, Elisa, Veronica Sciannameo, Sebastian Dorin Asaftei, et al.. (2023). Prolonged 14-day continuous infusion of high-dose ifosfamide (14IFO) for relapsed/refractory high-grade osteosarcoma (R/R HOS): A retrospective multicenter cohort study.. Journal of Clinical Oncology. 41(16_suppl). 11534–11534.
5.
Morelli, Mariangela, Francesca Lessi, Chiara Maria Mazzanti, et al.. (2023). Identification of New Potential Prognostic and Predictive Markers in High-Grade Osteosarcoma Using Whole Exome Sequencing. International Journal of Molecular Sciences. 24(12). 10086–10086. 4 indexed citations
6.
Luksch, Roberto, Giuseppe Maria Milano, Francesco Barretta, et al.. (2021). Efficacy of dose intensification in induction therapy for localized Ewing sarcoma: Italian Sarcoma Group (ISG) and Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP) ISG/AIEOP EW-1 study.. Journal of Clinical Oncology. 39(15_suppl). 11501–11501. 3 indexed citations
7.
Calvani, Maura, Marina Vignoli, Giovanni Beltrami, et al.. (2020). Preliminary Study on β3-Adrenoreceptor as Predictor Marker of Relapse in Ewing Sarcoma Patients. Biomedicines. 8(10). 413–413. 4 indexed citations
9.
Puma, Nadia, Anna Paioli, Gianni Bisogno, et al.. (2020). Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group/AIEOP EW-2 study.. Journal of Clinical Oncology. 38(15_suppl). 10517–10517. 4 indexed citations
10.
Affinita, Maria Carmen, Andrea Ferrari, Giuseppe Maria Milano, et al.. (2017). Long‐term results in children with head and neck rhabdomyosarcoma: A report from the Italian Soft Tissue Sarcoma Committee. Pediatric Blood & Cancer. 65(3). 19 indexed citations
11.
Palmerini, Emanuela, Robin L. Jones, Emanuela Marchesi, et al.. (2016). Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer. 16(1). 280–280. 72 indexed citations
12.
Palmerini, Emanuela, Robin L. Jones, Anna Paioli, et al.. (2014). Gemcitibine (G) and docetaxel (D) in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy.. Journal of Clinical Oncology. 32(15_suppl). 10541–10541. 1 indexed citations
13.
Ghirri, Paolo, Marco Bernardini, Marco Vuerich, et al.. (2001). Adrenarche ,pubertal development ,age at menarche and final height of full-term ,born small for gestational age (SGA) girls. Gynecological Endocrinology. 15(2). 91–97. 69 indexed citations
14.
Santini, Ferruccio, Luca Chiovato, Paolo Ghirri, et al.. (1999). Serum Iodothyronines in the Human Fetus and the Newborn: Evidence for an Important Role of Placenta in Fetal Thyroid Hormone Homeostasis1. The Journal of Clinical Endocrinology & Metabolism. 84(2). 493–498. 85 indexed citations
15.
Ghirri, Paolo, Luca Coccoli, Marco Bernardini, et al.. (1999). Symptomatic hypercalcemia in the first months of life: Calcium-regulating hormones and treatment. Journal of Endocrinological Investigation. 22(5). 349–353. 13 indexed citations
16.
Ghirri, Paolo, et al.. (1997). Final height in girls with slowly progressive untreated central precocious puberty. Gynecological Endocrinology. 11(5). 301–305. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026